{"disease":{"id":"autoimmune-myasthenia-gravis","name":"autoimmune myasthenia gravis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04806620","title":"Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Brain Inflammation Collaborative","has_results":false},{"nct_id":"NCT07333196","title":"Tongji NADs Cohort","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1550,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT05408702","title":"Exercise in Autoimmune Myasthenia Gravis and Myasthenic Syndromes","phase":"","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"Institut de Myologie, France","has_results":false},{"nct_id":"NCT03941184","title":"Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity","phase":"","overall_status":"COMPLETED","enrollment_count":114,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04561557","title":"Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT05214612","title":"Predictors and Prognostic Factors of Myasthenia Gravis Outcome","phase":"","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT07526493","title":"Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":6,"lead_sponsor_name":"Tongji Hospital","has_results":false}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}